
Mesothelioma - Pipeline Insight, 2025
Description
DelveInsight’s, “Mesothelioma - Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Mesothelioma: Overview
Mesothelioma is a rare and aggressive cancer linked to asbestos exposure, particularly the amosite and crocidolite types. It primarily affects the pleura (lining of the lungs) but can also develop in the peritoneum and pericardium. With a long latency period, the disease is more common in individuals exposed to asbestos in high-risk industries like shipbuilding. Although the overall incidence has declined with better regulations, mesothelioma remains prevalent in areas with past asbestos exposure. Men are more frequently diagnosed than women, and many patients are diagnosed at advanced stages, often when the disease is harder to treat.
Malignant mesothelioma is primarily linked to asbestos exposure, which is believed to cause repeated inflammation, interference with cell division, activation of proto-oncogenes, and free radical production. Other contributing factors include ionizing radiation (such as mantle radiation for Hodgkin lymphoma) and genetic mutations, particularly in the BRCA 1 Associated Protein (BAP1) gene. While smoking does not directly cause mesothelioma, it significantly increases the risk of lung cancer when combined with asbestos exposure. High-risk occupations include shipbuilding, mining, ceramics, cement manufacturing with asbestos, auto parts manufacturing (especially brake lining), paper mills, insulation work, and railroad repair. Genetic factors, including chromosomal anomalies such as the loss of chromosome 22, may increase susceptibility to the disease. There is no evidence linking alcohol, tobacco, or dietary intake to mesothelioma.
Malignant mesothelioma is classified into three histological types: epithelioid, sarcomatoid, and mixed, with the epithelioid type generally associated with better outcomes. The tumor often begins as multiple nodules on the parietal pleura, spreading locally to the visceral pleura, and may extend to the chest wall, diaphragm, or mediastinum. Lymph node involvement follows a distinct pattern compared to lung cancer, with metastasis typically occurring through direct local invasion to the bronchopulmonary or hilar nodes, followed by the carinal, internal mammary, or peridiaphragmatic nodes. Lymph node involvement is relatively uncommon in malignant pleural mesothelioma, and spread tends to be local rather than distant.
The treatment of mesothelioma involves surgery, chemotherapy, radiotherapy, and palliative care. Surgery is recommended for medically fit patients, while chemotherapy with cisplatin and pemetrexed is the standard treatment for most cases. Palliative care options, such as talc pleurodesis for pleural effusions and radiotherapy for symptom management, help improve quality of life. New treatments, like photodynamic therapy, are being explored, but the focus remains on symptom control and disease management. Multidisciplinary teams are crucial in developing individualized treatment plans based on the patient's overall health and disease stage. Despite advances in treatment, the prognosis remains poor, and ongoing research aims to find more effective therapies. Supportive care is essential for managing symptoms and improving the patient's quality of life.
""Mesothelioma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mesothelioma pipeline landscape is provided which includes the disease overview and Mesothelioma treatment guidelines. The assessment part of the report embraces, in depth Mesothelioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Mesothelioma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mesothelioma Emerging Drugs
Further product details are provided in the report……..
Mesothelioma: Therapeutic Assessment
This segment of the report provides insights about the different Mesothelioma drugs segregated based on following parameters that define the scope of the report, such as:
Mesothelioma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Mesothelioma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mesothelioma drugs.
Mesothelioma Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Mesothelioma: Overview
Mesothelioma is a rare and aggressive cancer linked to asbestos exposure, particularly the amosite and crocidolite types. It primarily affects the pleura (lining of the lungs) but can also develop in the peritoneum and pericardium. With a long latency period, the disease is more common in individuals exposed to asbestos in high-risk industries like shipbuilding. Although the overall incidence has declined with better regulations, mesothelioma remains prevalent in areas with past asbestos exposure. Men are more frequently diagnosed than women, and many patients are diagnosed at advanced stages, often when the disease is harder to treat.
Malignant mesothelioma is primarily linked to asbestos exposure, which is believed to cause repeated inflammation, interference with cell division, activation of proto-oncogenes, and free radical production. Other contributing factors include ionizing radiation (such as mantle radiation for Hodgkin lymphoma) and genetic mutations, particularly in the BRCA 1 Associated Protein (BAP1) gene. While smoking does not directly cause mesothelioma, it significantly increases the risk of lung cancer when combined with asbestos exposure. High-risk occupations include shipbuilding, mining, ceramics, cement manufacturing with asbestos, auto parts manufacturing (especially brake lining), paper mills, insulation work, and railroad repair. Genetic factors, including chromosomal anomalies such as the loss of chromosome 22, may increase susceptibility to the disease. There is no evidence linking alcohol, tobacco, or dietary intake to mesothelioma.
Malignant mesothelioma is classified into three histological types: epithelioid, sarcomatoid, and mixed, with the epithelioid type generally associated with better outcomes. The tumor often begins as multiple nodules on the parietal pleura, spreading locally to the visceral pleura, and may extend to the chest wall, diaphragm, or mediastinum. Lymph node involvement follows a distinct pattern compared to lung cancer, with metastasis typically occurring through direct local invasion to the bronchopulmonary or hilar nodes, followed by the carinal, internal mammary, or peridiaphragmatic nodes. Lymph node involvement is relatively uncommon in malignant pleural mesothelioma, and spread tends to be local rather than distant.
The treatment of mesothelioma involves surgery, chemotherapy, radiotherapy, and palliative care. Surgery is recommended for medically fit patients, while chemotherapy with cisplatin and pemetrexed is the standard treatment for most cases. Palliative care options, such as talc pleurodesis for pleural effusions and radiotherapy for symptom management, help improve quality of life. New treatments, like photodynamic therapy, are being explored, but the focus remains on symptom control and disease management. Multidisciplinary teams are crucial in developing individualized treatment plans based on the patient's overall health and disease stage. Despite advances in treatment, the prognosis remains poor, and ongoing research aims to find more effective therapies. Supportive care is essential for managing symptoms and improving the patient's quality of life.
""Mesothelioma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mesothelioma pipeline landscape is provided which includes the disease overview and Mesothelioma treatment guidelines. The assessment part of the report embraces, in depth Mesothelioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Mesothelioma R&D. The therapies under development are focused on novel approaches to treat/improve Mesothelioma.
This segment of the Mesothelioma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mesothelioma Emerging Drugs
- Pegargiminase: Polaris Pharmaceuticals
- Volrustomig: AstraZeneca
- Tremelimumab: MedImmune LLC
- TAK-500: Takeda
- RSO-021: RS Oncology LLC
Further product details are provided in the report……..
Mesothelioma: Therapeutic Assessment
This segment of the report provides insights about the different Mesothelioma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Mesothelioma
- There are approx. 45+ key companies which are developing the therapies for Mesothelioma. The companies which have their Mesothelioma drug candidates in the most advanced stage, i.e. Preregistration include, Polaris Pharmaceuticals.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Mesothelioma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Mesothelioma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mesothelioma drugs.
Mesothelioma Report Insights
- Mesothelioma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Mesothelioma drugs?
- How many Mesothelioma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mesothelioma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mesothelioma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Mesothelioma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Polaris Pharmaceuticals
- AstraZeneca
- MedImmune LLC
- Takeda
- RS Oncology LLC
- Vivace Therapeutics, Inc
- VM Oncology, LLC
- KaliVir Immunotherapeutics
- UTC Therapeutics Inc.
- Tango Therapeutics, Inc.
- Verismo Therapeutics
- SpringWorks Therapeutics, Inc.
- Gilead Sciences
- Nurix Therapeutics, Inc.
- Amphera BV
- Merck Sharp & Dohme LLC
- Constellation Pharmaceuticals
- BridGene Biosciences Inc.
- Aromics Therapeutics
- Ascentage Pharma Group Inc.
- 7 Hills Pharma, LLC
- Pegargiminase
- Volrustomig
- Tremelimumab
- TAK-500
- RSO-021
- VT3989
- VMD-928
- VET3-TG
- UCMYM802 Injection
- TNG908
- SynKIR-110
- SW-682
- Sacituzumab
- NX-1607
- MesoPher
- Lenvatinib
- CPI-0209
- BGC515
- AROG4-01
- APG-2449
- Alintegimod
Key Players
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Mesothelioma: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Mesothelioma– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- Pegargiminase: Polaris Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Tremelimumab: MedImmune LLC
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- TAK-500: Takeda
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Mesothelioma Key Companies
- Mesothelioma Key Products
- Mesothelioma- Unmet Needs
- Mesothelioma- Market Drivers and Barriers
- Mesothelioma- Future Perspectives and Conclusion
- Mesothelioma Analyst Views
- Mesothelioma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.